Clinical trial data
Ventyx Halts TYK2 Inhibitor Despite Phase 2 Success, Stock Plummets 70%
Ventyx Biosciences discovered that even a seemingly successful clinical trial may not be enough to support a drug’s advancement, as ...
Imbria Pharmaceuticals Clears Safety Hurdles in Phase 2 Heart Failure Trial, Paving the Way for Promising Late-Stage Development
Imbria Pharmaceuticals has achieved positive results in a phase 2 trial for its heart failure medication. The Boston-based biotech, in ...
Novartis’ $3.2B Chinook Investment Soars with Successful Phase 3 Endpoint, Paving the Way for 2024 FDA Filing
Novartis is seeing promising results from its substantial $3.2 billion investment in Chinook Therapeutics. Exciting top-line data from a phase ...
Alnylam, Biogen show gene-silencing data for Alzheimer’s therapies
This week, Alnylam and Biogen took a significant step toward redefining the landscape of Alzheimer’s disease treatment by revealing promising ...
Araclon’s Alzheimer’s vaccine shows promise in phase 2 trial
Araclon Biotech, a subsidiary of Grifols, has unveiled promising early evidence regarding the effectiveness of its Alzheimer’s disease vaccine. In ...
J&J’s dengue pill shows antiviral activity in human trial, could prevent millions of infections
Amidst Johnson & Johnson’s strategic restructuring in the infectious disease and vaccine divisions, one resilient contender has emerged. JNJ-1802, an ...
Evelo seeks new partner after microbiome platform fails to beat placebo
In a series of unfortunate turns, Evelo Biosciences, a biotech company backed by Flagship Ventures and that went public in ...
Leo Pharma reveals positive results for its JAK cream in hand eczema, competing with Incyte’s Opzelura
In February, Leo Pharma created a buzz by announcing the success of its JAK-inhibitor cream, delgocitinib, in a phase 3 ...
Lilly’s mirikizumab shows promise in Crohn’s disease after failing in psoriasis
After a previous setback when the FDA withheld approval for mirikizumab in ulcerative colitis due to manufacturing issues, Eli Lilly’s ...
Immunic’s MS drug shows positive biomarker results in phase 2 trial, boosting investor confidence
Immunic Therapeutics’ strategic decision to refocus its efforts earlier this year appears to be yielding positive results, drawing favorable reactions ...
Merck’s Keytruda extends survival of early lung cancer patients in trial, awaits FDA approval
Merck & Co.’s Keytruda has achieved a groundbreaking milestone in the treatment landscape for early-stage non-small cell lung cancer (NSCLC), ...
Anaptys reports positive results for its rare skin disease drug and seeks a partner for commercialization
AnaptysBio has unveiled promising phase 3 data for its rare skin disease drug candidate, indicating a potential challenge to Boehringer ...
Neurocrine reports positive phase 3 data for hyperplasia drug in children
Just a month after the successful outcome of Neurocrine Biosciences’ phase 3 study for crinecerfont in adults with hyperplasia, the ...
Keytruda shows promise in bladder cancer trial, Merck says
Merck’s immunotherapy drug, Keytruda, continues to demonstrate success in the field of bladder cancer. After securing FDA approvals for use ...
ALX Oncology’s CD47 Drug Shows Enhanced Response in Solid Tumors, Aiming for Phase 3 Trials
ALX Oncology is reevaluating the potential of its anti-CD47 drug in the context of solid tumors, buoyed by promising data. ...
Syndax Halts Pivotal Cancer Trial Prematurely Due to Efficacy, Stock Dips Amid Disappointing Details
Syndax Pharmaceuticals, based in Massachusetts, has made a significant decision to prematurely conclude a pivotal cancer clinical trial, leading to ...
Venclexta fails to meet primary endpoint in multiple myeloma trial
AbbVie and Roche, pioneers in the field of leukemia treatments with Venclexta, faced a setback as their hopes to expand ...
Structure posts promising results for oral obesity drug, but delays further data due to error
Structure Therapeutics has offered an initial glimpse into the effectiveness of its oral GLP-1 receptor agonist, reporting a notable 5% ...
Evommune abandons EVO101, a topical IRAK4 inhibitor, for atopic dermatitis
Evommune, a California-based biotech company, has made the strategic decision to discontinue its sole clinical-stage asset, EVO101, following a thorough ...
Magrolimab fails to improve survival in leukemia, Gilead halts trial
Another failure has occurred in Gilead Sciences’ $4.9 billion immuno-oncology wager. Following an ad hoc analysis of a phase 3 ...
Influential Pliant Persuades Investors, Propelling Stock Skyward with Promising Liver Disease Efficacy Data
Pliant Therapeutics has captured the attention of investors with compelling early clinical findings regarding its lead drug candidate’s potential to ...
Ionis’ olezarsen slashes triglycerides and pancreatitis in rare disease patients
Ionis Pharmaceuticals has achieved a significant milestone in its phase 3 clinical trial for lipid-lowering therapy, bringing the company closer ...
MDMA shows promise for PTSD treatment in second phase 3 trial, paving way for FDA approval
MAPS Public Benefit Corporation has recently unveiled phase 3 data, marking a significant milestone in its quest for FDA approval ...
Acelyrin’s lead drug flops in phase 3 trial, wiping out half of its market value
Acelyrin, a biotech company based in Los Angeles, has delivered a shocking blow to its investors. Despite successfully raising an ...
Merck showcases new data on sotatercept for PAH, awaits FDA decision
Merck & Co. has unveiled new clinical data on sotatercept, reinforcing the drug candidate’s safety and efficacy in the treatment ...
Vaxart’s Oral Norovirus Vaccine Misses Primary Endpoint But Shows Some Efficacy In Phase 2
Vaxart finds itself in a precarious position as it grapples with mixed results for its oral monovalent norovirus vaccine candidate, ...
Pfizer’s Lyme Vaccine Shows Strong Booster And Pediatric Effects In Phase 2
Pfizer and Valneva are making strides in their Lyme disease vaccine program, achieving a significant milestone by demonstrating the safety ...
Roche’s $310 Million Gamble On Alnylam Pays Off As Hypertension Drug Shows Promise In Phase 2
Roche’s recent investment of $310 million into metabolic therapy is yielding positive results, as its collaboration with Alnylam in the ...
Regeneron Faces New Challenges as Biosimilars Target Eylea Market Dominance, Novartis’ Sandoz Takes Aim with Therapeutic Equivalence
Regeneron finds itself at a crossroads as its blockbuster eye drug Eylea contends with an FDA rejection and growing competition ...
